Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07634536 · ClinicalTrials.gov registry record · Phase 2
Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant
A Phase 2 study, sponsored by Stanford University.
- Not yet
- Registry status
- Phase 2
- Development phase
- 30
- Enrollment target
NCT07634536: Clinical Trial Phase 2 study, sponsored by Stanford University.
NCT07634536 is a Phase 2 study that has not yet begun recruiting, run by Stanford University. The registered enrollment target is 30 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07634536, a Phase 2 study, has not yet begun recruiting, sponsored by Stanford University.
- NOT YET RECRUITING
- Registry status
- Phase 2
- Development phase
- 30 participants
- Enrollment target
Study Summary
Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity. Total marrow and lymphoid irradiation (TMLI) is a specialized radiation technique that specifically targets marrow and lymphoid tissue to maximize antitumor efficacy while reducing off target toxicity. Despite these benefits, TMLI is technically challenging and time consuming. The radiation oncology team at Stanford has developed an automated TMLI platform to overcome these challenges. In this phase II trial, automation will be incorporated into a previously validated conditioning regimen of fludarabine/cyclophosphamide/TMLI HCT with post-transplant cyclophosphamide (PTCy) for graft-versus-host disease (GVHD) prophylaxis to confirm the feasibility and safety of automation in patients receiving allogeneic HCT for high-risk myeloid malignancies.
Primary Outcome
Death without prior disease relapse following allogeneic peripheral blood stem cell transplantation.
Interventions
- DRUG Cyclophosphamide
- DRUG Fludarabine
- DRUG Mycophenolate mofetil (MMF)
- RADIATION VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI)
- BIOLOGICAL Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 2026-08 |
| Est. Completion | 2028-08 |
| Phase | Phase 2 |
What is known before NCT07634536 opens enrollment
NCT07634536 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 30 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (77% lower).
The record links to 0 conditions, and to 5 interventions - of which Cyclophosphamide is the first listed.
NCT07634536 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07634536 about?
NCT07634536 is a clinical study titled "Automated Total Marrow and Lymphoid Irradiation for Allogeneic Hematopoietic Cell Transplant". Intensive conditioning regimens used in allogeneic hematopoietic cell transplant (HCT) help to eliminate hematologic tumors and reduce the risk of relapse, but are also characterized by high toxicity. Total marrow and lymphoid irradiation (TMLI) is a specialized radiation technique that specifically...
What is the current status of trial NCT07634536?
This trial is currently not yet recruiting. It is a Phase 2 study. The enrollment target is 30 participants. The study started on 2026-08. Estimated completion is 2028-08.
What interventions are being tested in trial NCT07634536?
The interventions under investigation include: Cyclophosphamide (DRUG), Fludarabine (DRUG), Mycophenolate mofetil (MMF) (DRUG), VMAT-Based Total Marrow and Lymphoid Irradiation (TMLI) (RADIATION), Allogeneic Peripheral Blood Stem Cell Transplantation (PBSCT) (BIOLOGICAL).
Who is sponsoring clinical trial NCT07634536?
This trial is sponsored by Stanford University, which has 1,744 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07634536's enrollment target sits among peer trials
30 1582nd of 2000 higher than 332 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00977977 · 30 participants · Phase 2
Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
- NCT01459107 · 30 participants · Phase 2
Human Upper Extremity Allotransplantation
- NCT01666080 · 30 participants · NA
Second or Greater Allogeneic Hematopoietic Stem Cell Transplant Using Reduced Intensity Conditioning (RIC)
- NCT01720836 · 30 participants · Phase 1
Study of the Immune Response of MUC1 (Mucin1) Peptide Vaccine for Non-small Cell Lung Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia